Fermented milk of Lactobacillus helveticus IDCC3801 reduces beta-amyloid and attenuates memory deficit

Journal of Functional Foods

Volumn 2, Issue 2, 2010, Pages 143-152

  Yeon, Seung Woo ^a   You, Young Sang ^a   Kwon, Hyuk Sang ^a   Yang, Eun Hee ^a   Ryu, Jung Su ^a   Kang, Byung Hwa ^a   Kang, Jae Hoon ^a  

^a ILDONG Pharmaceutical Co   (South Korea)

Author keywords

Secretase; Alzheimer's disease; Amyloid; L. helveticus; Probiotic

Indexed keywords

LACTOBACILLUS HELVETICUS; RATTUS;

EID: 77954860410     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2010.04.002     Document Type: Article

References (36)

1. Bejar C., Wang R.H., Weinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. European Journal of Pharmacology 1999, 383:231-240.
2. Best J.D., Jay M.T., Otu F., Ma J., Nadin A., Ellis S., Lewis H.D., Pattison C., Reilly M., Harrison T., Shearman M.S., Williamson T.L., Atack J.R. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6, 7-dihydro-5H-dibenzo[b, d]azepin-7-yl]-L-alaninamide]. The Journal of Pharmacology and Experimental Therapeutics 2005, 313:902-908.
3. Cheng H., Vetrivel K.S., Gong P., Meckler X., Parent A., Thinakaran G. Mechanisms of disease: new therapeutic strategies for Alzheimer's disease-targeting APP processing in lipid rafts. Nature Clinical Practice. Neurology 2007, 3:374-382.
4. Claasen A.M., Guevremont D., Mason-Parker S.E., Bourne K., Tate W.P., Abraham W.C., Abraham J.M. Secreted amyloid precursor protein-alpha upregulates synaptic protein synthesis by a protein kinase G-dependent mechanism. Neuroscience Letters 2009, 460:92-96.
5. de Angelis L., Furlan C. The effects of ascorbic acid and oxiracetam on scopolamine-induced amnesia in a habituation test in aged mice. Neurobiology of Learning and Memory 1995, 64:119-124.
6. D'hooge R., De Deyn P.P. Applications of the Morris water maze in the study of learning and memory. Brain Research. Brain Research Reviews 2001, 36:60-90.
7. Donahue J.E., Flaherty S.L., Johanson C.E., Duncan J.A., Silverberg G.D., Miller M.C., Tavares R., Yang W., Wu Q., Sabo E., Hovanesian V., Stopa E.G. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathologica 2006, 112:405-415.
8. Ebringer L., Ferencik M., Krajcovic J. Beneficial health effects of milk and fermented dairy products-review. Folia Microbiologica (Praha) 2008, 53:378-394.
9. El Mouedden M., Vandermeeren M., Meert T., Mercken M. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors. Current Pharmaceutical Design 2006, 12:671-676.
10. Gage F.H., Bjorklund A. Cholinergic septal grafts into the hippocampal formation improve spatial learning and memory in aged rats by an atropine-sensitive mechanism. The Journal of Neuroscience 1986, 6:2837-2847.
11. Gandy S., Greengard P. Regulated cleavage of the Alzheimer amyloid precursor protein: molecular and cellular basis. Biochimie 1994, 76:300-303.
12. Ghosh A.K., Gemma S., Tang J. Beta-secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 2008, 5:399-408.
13. Gupta V., Garg R. Probiotics. Indian Journal of Medical Microbiology 2009, 27:202-209.
14. Hansen R.A., Gartlehner G., Webb A.P., Morgan L.C., Moore C.G., Jonas D.E. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clinical Interventions in Aging 2008, 3:211-225.
15. Hills I.D., Vacca J.P. Progress toward a practical BACE-1 inhibitor. Current Opinion in Drug Discovery & Development 2007, 10:383-391.
16. Hiramatsu M., Murasawa H., Nabeshima T., Kameyama T. Effects of U-50, 488H on scopolamine-, mecamylamine- and dizocilpine-induced learning and memory impairment in rats. The Journal of Pharmacology and Experimental Therapeutics 1998, 284:858-867.
17. Kelley R.E., Minagar A. Memory complaints and dementia. The Medical Clinics of North America 2009, 93(ix):389-406.
18. Kopelman M.D., Corn T.H. Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. Brain 1988, 111(Pt 5):1079-1110.
19. Kwon H.S., Yang E.H., Lee S.H., Yeon S.W., Kang B.H., Kim T.Y. Rapid identification of potentially probiotic Bifidobacterium species by multiplex PCR using species-specific primers based on the region extending from 16S rRNA through 23S rRNA. FEMS Microbiology Letters 2005, 250:55-62.
20. Kwon H.S., Yang E.H., Yeon S.W., Kang B.H., Kim T.Y. Rapid identification of probiotic Lactobacillus species by multiplex PCR using species-specific primers based on the region extending from 16S rRNA through 23S rRNA. FEMS Microbiology Letters 2004, 239:267-275.
21. Matar C., Amiot J., Savoie L., Goulet J. The effect of milk fermentation by Lactobacillus helveticus on the release of peptides during in vitro digestion. Journal of Dairy Science 1996, 79:971-979.
22. Mohajeri M.H., Leuba G. Prevention of age-associated dementia. Brain Research Bulletin 2009, 80:315-325.
23. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. Journal of Neuroscience Methods 1984, 11:47-60.
24. Nakamura Y., Yamamoto N., Sakai K., Okubo A., Yamazaki S., Takano T. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. Journal of Dairy Science 1995, 78:777-783.
25. Nitta A., Itoh A., Hasegawa T., Nabeshima T. Beta-Amyloid protein-induced Alzheimer's disease animal model. Neuroscience Letters 1994, 170:63-66.
26. Robert M.C., Razaname A., Mutter M., Juillerat M.A. Identification of angiotensin-I-converting enzyme inhibitory peptides derived from sodium caseinate hydrolysates produced by Lactobacillus helveticus NCC 2765. Journal of Agricultural and Food Chemistry 2004, 52:6923-6931.
27. Rubaj A., Zgodzinski W., Sieklucka-Dziuba M. The influence of adenosine A3 receptor agonist: IB-MECA, on scopolamine- and MK-801-induced memory impairment. Behavioural Brain Research 2003, 141:11-17.
28. Sabbagh M.N. Drug development for Alzheimer's disease: where are we now and where are we headed?. The American Journal of Geriatric Pharmacotherapy 2009, 7:167-185.
29. Selkoe D.J. Molecular pathology of amyloidogenic proteins and the role of vascular amyloidosis in Alzheimer's disease. Neurobiology of Aging 1989, 10:387-395.
30. Shah N.P. Functional cultures and health benefits. International Dairy Journal 2007, 17:1262-1277.
31. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Analytical Biochemistry 1985, 150:76-85.
32. Takeuchi M., Yamagishi S. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Current Pharmaceutical Design 2008, 14:973-978.
33. Ueno K., Mizuno S., Yamamoto N. Purification and characterization of an endopeptidase that has an important role in the carboxyl terminal processing of antihypertensive peptides in Lactobacillus helveticus CM4. Letters in Applied Microbiology 2004, 39:313-318.
34. Vasiljevic T., Shah N.P. Probiotics-From Metchnikoff to bioactives. International Dairy Journal 2008, 18:714-728.
35. Wolfe M.S. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics 2008, 5:391-398.
36. Yeon S.W., Jeon Y.J., Hwang E.M., Kim T.Y. Effects of peptides derived from BACE1 catalytic domain on APP processing. Peptides 2007, 28:838-844.